CO7020910A2 - Derivados de aza adamantano y los usos de los mismos - Google Patents
Derivados de aza adamantano y los usos de los mismosInfo
- Publication number
- CO7020910A2 CO7020910A2 CO14158009A CO14158009A CO7020910A2 CO 7020910 A2 CO7020910 A2 CO 7020910A2 CO 14158009 A CO14158009 A CO 14158009A CO 14158009 A CO14158009 A CO 14158009A CO 7020910 A2 CO7020910 A2 CO 7020910A2
- Authority
- CO
- Colombia
- Prior art keywords
- adamantane
- aza derivatives
- aza
- derivatives
- adamantane aza
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN4526CH2011 | 2011-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO7020910A2 true CO7020910A2 (es) | 2014-08-11 |
Family
ID=54258978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO14158009A CO7020910A2 (es) | 2011-12-22 | 2014-07-22 | Derivados de aza adamantano y los usos de los mismos |
Country Status (20)
Country | Link |
---|---|
US (1) | US9303016B2 (es) |
EP (2) | EP3266783A1 (es) |
JP (1) | JP6180432B2 (es) |
KR (1) | KR102029516B1 (es) |
CN (1) | CN104125960A (es) |
AU (1) | AU2012367780B2 (es) |
BR (1) | BR112014015298B1 (es) |
CA (1) | CA2860192C (es) |
CL (1) | CL2014001705A1 (es) |
CO (1) | CO7020910A2 (es) |
IL (1) | IL233269A0 (es) |
MA (1) | MA35875B1 (es) |
MX (1) | MX358696B (es) |
MY (1) | MY192815A (es) |
NZ (1) | NZ626744A (es) |
PH (1) | PH12014501441A1 (es) |
RU (1) | RU2672468C1 (es) |
SG (1) | SG11201403266RA (es) |
WO (1) | WO2013111150A1 (es) |
ZA (1) | ZA201405265B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
AP2014007796A0 (en) | 2011-12-22 | 2014-07-31 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
TW201613919A (en) | 2014-07-02 | 2016-04-16 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
EP3349752B1 (en) * | 2015-08-11 | 2021-06-30 | Connexios Life Sciences Pvt. Ltd. | Aza-adamantane compound for wound healing |
TWI748194B (zh) | 2018-06-28 | 2021-12-01 | 德商菲尼克斯 Fxr有限責任公司 | 含有雙環核心部分之新穎lxr調節劑 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1125922A1 (en) | 1998-11-02 | 2001-08-22 | Welfide Corporation | Pyrrolidine compounds and medicinal utilization thereof |
ATE482747T1 (de) * | 2003-04-11 | 2010-10-15 | High Point Pharmaceuticals Llc | Neue amide derivate und deren pharmazeutische verwendungen |
DE602005016446D1 (de) * | 2004-11-05 | 2009-10-15 | Theravance Inc | 5-HT4-Rezeptoragonistenverbindungen |
KR101302627B1 (ko) * | 2005-01-05 | 2013-09-10 | 아비에 인코포레이티드 | 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제 |
US20090005363A1 (en) * | 2005-12-20 | 2009-01-01 | Ralf Glatthar | Organic Compounds |
CA2685036A1 (en) * | 2007-04-24 | 2008-11-06 | High Point Pharmaceuticals, Llc | Pharmaceutical use of substituted amides |
GB0803494D0 (en) * | 2008-02-26 | 2008-04-02 | Sterix Ltd | Compound |
EP2280966A1 (en) | 2008-03-14 | 2011-02-09 | Exelixis, Inc. | Azabicyclo [3.2.1]octyl derivatives as 11 beta-hsd1 modulators |
WO2009138386A2 (en) | 2008-05-13 | 2009-11-19 | Boehringer Ingelheim International Gmbh | Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use |
TW201022266A (en) * | 2008-10-23 | 2010-06-16 | Boehringer Ingelheim Int | Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use |
EP2423212B1 (en) * | 2009-04-24 | 2016-06-01 | Nissan Chemical Industries, Ltd. | Process for production of 2-azaadamantane compound from bicyclocarbamate compound |
EA020227B1 (ru) * | 2009-09-14 | 2014-09-30 | Сувен Лайф Сайенсиз Лимитед | 1,2-дигидро-2-оксохинолиновые соединения в качестве лигандов рецептора 5-нт |
-
2012
- 2012-12-21 JP JP2014548340A patent/JP6180432B2/ja not_active Expired - Fee Related
- 2012-12-21 AU AU2012367780A patent/AU2012367780B2/en not_active Ceased
- 2012-12-21 KR KR1020147020456A patent/KR102029516B1/ko active IP Right Grant
- 2012-12-21 BR BR112014015298-5A patent/BR112014015298B1/pt not_active IP Right Cessation
- 2012-12-21 EP EP17170011.5A patent/EP3266783A1/en not_active Withdrawn
- 2012-12-21 SG SG11201403266RA patent/SG11201403266RA/en unknown
- 2012-12-21 NZ NZ626744A patent/NZ626744A/en not_active IP Right Cessation
- 2012-12-21 US US14/367,814 patent/US9303016B2/en not_active Expired - Fee Related
- 2012-12-21 WO PCT/IN2012/000842 patent/WO2013111150A1/en active Application Filing
- 2012-12-21 MY MYPI2014001837A patent/MY192815A/en unknown
- 2012-12-21 EP EP12844669.7A patent/EP2794607B1/en not_active Not-in-force
- 2012-12-21 CA CA2860192A patent/CA2860192C/en active Active
- 2012-12-21 RU RU2014126647A patent/RU2672468C1/ru active
- 2012-12-21 CN CN201280070435.2A patent/CN104125960A/zh active Pending
- 2012-12-21 MX MX2014007717A patent/MX358696B/es active IP Right Grant
-
2014
- 2014-06-19 IL IL233269A patent/IL233269A0/en unknown
- 2014-06-20 PH PH12014501441A patent/PH12014501441A1/en unknown
- 2014-06-23 CL CL2014001705A patent/CL2014001705A1/es unknown
- 2014-07-18 ZA ZA2014/05265A patent/ZA201405265B/en unknown
- 2014-07-20 MA MA37228A patent/MA35875B1/fr unknown
- 2014-07-22 CO CO14158009A patent/CO7020910A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2860192A1 (en) | 2013-08-01 |
RU2672468C1 (ru) | 2018-11-15 |
AU2012367780B2 (en) | 2017-04-06 |
PH12014501441B1 (en) | 2014-10-08 |
EP3266783A1 (en) | 2018-01-10 |
PH12014501441A1 (en) | 2014-10-08 |
US9303016B2 (en) | 2016-04-05 |
SG11201403266RA (en) | 2014-07-30 |
IL233269A0 (en) | 2014-08-31 |
KR20140107566A (ko) | 2014-09-04 |
EP2794607B1 (en) | 2017-05-10 |
EP2794607A1 (en) | 2014-10-29 |
BR112014015298A8 (pt) | 2017-07-04 |
MX358696B (es) | 2018-08-31 |
KR102029516B1 (ko) | 2019-10-07 |
MA35875B1 (fr) | 2014-12-01 |
BR112014015298A2 (pt) | 2017-06-13 |
ZA201405265B (en) | 2017-11-29 |
JP2015500872A (ja) | 2015-01-08 |
MY192815A (en) | 2022-09-09 |
CN104125960A (zh) | 2014-10-29 |
CL2014001705A1 (es) | 2014-11-21 |
JP6180432B2 (ja) | 2017-08-16 |
BR112014015298B1 (pt) | 2021-06-15 |
US20150141650A1 (en) | 2015-05-21 |
WO2013111150A1 (en) | 2013-08-01 |
MX2014007717A (es) | 2015-03-03 |
CA2860192C (en) | 2020-10-27 |
NZ626744A (en) | 2016-05-27 |
AU2012367780A1 (en) | 2014-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6821892A2 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
CO7061078A2 (es) | Compuestos de enediino, conjugados de los mismos y sus usos y metodos | |
CO6801640A2 (es) | Ensayos interrogatorios basados en células y usos de los mismos | |
CO7020859A2 (es) | Anticuerpos anti-cd134 (ox40) y usos de los mismos | |
CO6940383A2 (es) | Anticuerpos anti-erbb3 y usos de los mismos | |
CR20150380A (es) | Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico | |
CO7030961A2 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
CO6821931A2 (es) | Inhibidores selectivos de la glicosidasa y usos de los mismos | |
CR20130168A (es) | Moduladores de receptores de estrògenos y usos de los mismos | |
CO6791608A2 (es) | Moduladores de la vía del complemento y usos de los mismos | |
CO6910164A2 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
BR112015006198A2 (pt) | conjunto de cadeira | |
CL2015000640A1 (es) | Variantes de hppd y métodos de uso | |
CR20140259A (es) | Compuestos novedosos de benzopirano, composiciones y usos de los mismos | |
BR112013007499A2 (pt) | piridazinonas - métodos de criação e usos | |
CO6940382A2 (es) | Agentes de ligación a vegf/dll4 y usos de los mismos | |
BR112015002512A2 (pt) | limpador interdental | |
CO7020910A2 (es) | Derivados de aza adamantano y los usos de los mismos | |
CO6990717A2 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
BR112013033098A2 (pt) | inibidores de glicosidade seletivos e usos dos mesmos | |
CO6940376A2 (es) | Anticuerpos anti-psgl-1 y usos de los mismos | |
DK2882714T3 (da) | (aza-)isoquinolinonderivater | |
CO6870031A2 (es) | Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos | |
CO7000778A2 (es) | Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico | |
CO7020877A2 (es) | Anticuerpos anti-asic1 y usos de los mismos |